Drug Type Small molecule drug |
Synonyms 2-PAM-chloride, Pralidoxime (INN), Pralidoxime chloride (USP) + [3] |
Target |
Action activators |
Mechanism AChE activators(Acetylcholinesterase activators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (11 Mar 1964), |
Regulation- |
Molecular FormulaC7H9ClN2O |
InChIKeyHIGSLXSBYYMVKI-UHFFFAOYSA-N |
CAS Registry51-15-0 |
Start Date01 Jun 2022 |
Sponsor / Collaborator- |
Start Date30 Jun 2020 |
Sponsor / Collaborator |
Start Date23 Jul 2018 |
Sponsor / Collaborator |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00469 | Pralidoxime Chloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Muscle Weakness | United States | 11 Mar 1964 | |
Myasthenia Gravis | United States | 11 Mar 1964 | |
Organophosphate Poisoning | United States | 11 Mar 1964 | |
Respiratory Insufficiency | United States | 11 Mar 1964 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |